Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 11-CH-0078 | Other Identifier | National Institutes of Health |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
Adrenocorticotropin (ACTH) secretion is normally exquisitely regulated through endogenous stimulation by corticotrophin-releasing hormone (CRH) and negative feedback inhibition by cortisol, resulting in a circadian rhythm of cortisol. Recent evidence suggests that older men, and younger men who are endurance-trained athletes, both have reduced sensitivity to negative feedback, and perhaps increased basal levels of cortisol and ACTH. To investigate these possibilities, we propose to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
Subjects will collect saliva during two evenings before additional testing, and will on the same evening collect urine for twelve hours, both for cortisol measurements. Blood samples will be collected to evaluate the response to dexamethasone. We also will assess ACTH and cortisol responses to medications that reduce negative inhibition of ACTH. This testing will occur in the evening and will include administration of the glucocorticoid antagonist mifepristone, the mineralocorticoid antagonist spironolactone, and/or a look-alike tablet, on four occasions.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sedentary young adults, SMCP | Experimental | Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone |
|
| Endurance-trained young athletes, SMCP | Experimental | Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone |
|
| Sedentary young adults, MSPC | Experimental | Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone |
|
| Endurance-trained young athletes, MSPC | Experimental | Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone |
|
| Sedentary young adults, CPSM |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mifepristone | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Suppressors After Dexamethasone | All subjects will take 0.25mg dexamethasone as an outpatient between 2300 and 2400h and will then report to the clinic by 0800h next day for the final visit. At the final visit, cortisol response to dexamethasone suppression was assessed. The cortisol response was dichotomized (suppression vs. non-suppression, using 1.8 ug/dL as the cutoff point) and compared between the two groups,Sedentary Young Adults and Endurance-trained Young Athletes. | cortisol measured between 8 and 9 after dexamethasone was taken between 11 PM and midnight |
| Measure | Description | Time Frame |
|---|---|---|
| Post-dexamethasone Cortisol Level | Cortisol obtained at 8-9 AM after dexamethasone taken between 11 pm and midnight |
Not provided
Men aged 18 to 30 years of age are required for the young endurance trained and sedentary groups; men aged 65-80 years for the older study group, who will meet criteria for sedentary men below. Women and children are excluded to enhance homogeneity of responses and avoid the influence of menstrual cyclicity on the HPA axis.
Sedentary:
Trained:
For all participants:
EXCLUSION CRITERIA:
For all participants:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lynnette K Nieman, M.D. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16019599 | Background | Bauer ME. Stress, glucocorticoids and ageing of the immune system. Stress. 2005 Mar;8(1):69-83. doi: 10.1080/10253890500100240. | |
| 6327758 | Background | Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab. 1984 Jul;59(1):25-8. doi: 10.1210/jcem-59-1-25. |
| Label | URL |
|---|---|
| NIH Clinical Center Detailed Web Page | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sedentary Young Adults, SMCP | Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone |
| FG001 | Endurance-trained Young Athletes, SMCP | Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone |
|
| Endurance-trained young athletes, CPSM | Experimental | Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone |
|
| Sedentary young adults,PCMS | Experimental | Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone |
|
| Endurance-trained young athletes,PCMS | Experimental | Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone |
|
|
| Placebo | Drug |
|
| Spironolactone | Drug |
|
|
| Combined | Drug |
|
|
| Dexamethasone | Drug |
|
|
| 17153542 | Background | Booth CK, Probert B, Forbes-Ewan C, Coad RA. Australian army recruits in training display symptoms of overtraining. Mil Med. 2006 Nov;171(11):1059-64. doi: 10.7205/milmed.171.11.1059. |
| FG002 | Sedentary Young Adults, MSPC | Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone |
| FG003 | Endurance-trained Young Athletes, MSPC | Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone |
| FG004 | Sedentary Young Adults, CPSM | Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone |
| FG005 | Endurance-trained Young Athletes, CPSM | Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone |
| FG006 | Sedentary Young Adults,PCMS | Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone |
| FG007 | Endurance-trained Young Athletes,PCMS | Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sedentary Young Adults, SMCP | Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone |
| BG001 | Endurance-trained Young Athletes, SMCP | Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone |
| BG002 | Sedentary Young Adults, MSPC | Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone |
| BG003 | Endurance-trained Young Athletes, MSPC | Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone |
| BG004 | Sedentary Young Adults, CPSM | Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone |
| BG005 | Endurance-trained Young Athletes, CPSM | Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone |
| BG006 | Sedentary Young Adults,PCMS | Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone |
| BG007 | Endurance-trained Young Athletes,PCMS | Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone |
| BG008 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex/Gender, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Body Mass Index | Mean | Standard Deviation | Kg/m^2 |
| |||||||||||||||
| Race | Count of Participants | Participants |
| ||||||||||||||||
| Total Fat Percent | Mean | Standard Deviation | percent |
| |||||||||||||||
| Fat mass | Mean | Standard Deviation | kg |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Suppressors After Dexamethasone | All subjects will take 0.25mg dexamethasone as an outpatient between 2300 and 2400h and will then report to the clinic by 0800h next day for the final visit. At the final visit, cortisol response to dexamethasone suppression was assessed. The cortisol response was dichotomized (suppression vs. non-suppression, using 1.8 ug/dL as the cutoff point) and compared between the two groups,Sedentary Young Adults and Endurance-trained Young Athletes. | Posted | Count of Participants | Participants | cortisol measured between 8 and 9 after dexamethasone was taken between 11 PM and midnight |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Post-dexamethasone Cortisol Level | Posted | Mean | Standard Deviation | mcg/dL | Cortisol obtained at 8-9 AM after dexamethasone taken between 11 pm and midnight |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Sedentary Young Adults | Sedentary young adults group consists of 19 subjects, each subject was randomized to one of the following four arms: Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone | 0 | 19 | 0 | 19 | 0 | 19 |
| EG001 | Atheletes | Endurance-trained Young Athletes group consists of 20 subjects, each subject was randomized to one of the following four arms: Spironolactone, Then Mifepristone, Then Combined, Then Placebo, Then Dexamethasone Mifepristone, Then Spironolactone, Then Placebo, Then Combined, Then Dexamethasone Combined, Then Placebo, Then Spironolactone, Then Mifepristone, Then Dexamethasone Placebo, Then Combined, Then Mifepristone, Then Spironolactone, Then Dexamethasone | 0 | 20 | 0 | 20 | 0 | 20 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Lynnette Nieman | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 301-496-4000 | niemanl@mail.nih.gov |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D015735 | Mifepristone |
| D013148 | Spironolactone |
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D004963 | Estrenes |
| D004962 | Estranes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D013259 | Steroids, Fluorinated |
Not provided
Not provided
| Unknown |
|
| Black |
|
| White |
|
| Unknown |
|
|
|
|